The U.S. government will pay drugmaker Pfizer nearly $5.3 billion for 10 million treatment courses of its potential COVID-19 treatment if regulators approve it. Pfizer asked the Food and Drug Administration on Tuesday to authorize the experimental pill, called Paxlovid.
Earlier this month, the company said Paxlovid cut the risk of hospitalization and death by nearly 90% in people with mild to moderate coronavirus infections. The drugmaker studied its pill in people who were unvaccinated and who faced the greatest risk from the virus due to age or health problems, such as obesity.
Anything you can say negative against Hydroxychloroquine or Ivermectin can be said about this pill. Only difference is that Hydroxychloroquine and Ivermectin were existing drugs without much room for profit, whereas Pfizer has some serious upside to their profits. Actually if you think about it, as long as the faces of the Government tell everyone that other drugs are bad and Pfizer is good, then Pfizer stands to make a great deal of money on another experimental drug that the FDA will likely fast track with almost no testing.
4 comments:
"The FDA is already reviewing a competing pill from Merck and will hold a public meeting on it later this month."
The Merck pill has already been approved in the UK
for some reason the FDA is slow walking it here....
How much is Pfizer in bed with the Biden administration and Fauci ?
Top of my head the Merck pill had zero Covid deaths in its trial (the placebo arm had I believe 8) while the Pfizer was advertised as 90% effective.
Either way, why are we mandating shots now and hiding the vaccine data ?
Merck’s Covid pill approved by UK regulator, a potential game changer in fighting the pandemic
Merck CEO Robert Davis told CNBC at the end of October that the drugmaker is ready to produce and distribute tens of millions of doses of its Covid antiviral pills if given regulatory approval.
https://www.cnbc.com/2021/11/04/merck-oral-covid-pill-approved-by-uk-in-world-first.html
why is Joe so slow ?
Risk Insights: What to Know About Merck’s New COVID-19 Pill
On 4th November, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved the first antiviral pill, molnupiravir, to be used in response to the coronavirus pandemic. It’s important for both employers and the general public to understand the new pill, how it will be distributed, and any potential side effects.
Clinical Study Findings
Molnupiravir, which will go by the brand name Lagevrio in the UK, was developed by Ridgeback Biotherapeutics and Merck Sharp & Dohme. An international clinical trial found that treatment with the pill decreased the risk of hospitalisation from COVID-19 by approximately 50 per cent. With 775 patients who had recently caught COVID-19, the trial findings were as follows:
7.3% of those given the drug were hospitalised, compared to 14.1% of patients given a placebo.
There were no deaths in the group given molnupiravir, but eight patients given a placebo later died of COVID-19.
Molnupiravir is a nucleoside analogue, which means it mimics some of the building blocks of ribonucleic acid (RNA). When coronavirus enters a cell, the virus needs to duplicate its RNA genome to form new viruses. Molnupiravir gets incorporated into burgeoning RNA strands and, once inside, works by introducing errors into the genetic code. This stops the virus from multiplying, reducing the severity of the disease.
Who Will the Pill Be For?
The elderly and those with underlying health conditions have typically experienced worse disease outcomes if exposed to COVID-19. Older people or those with existing ailments often find it harder to produce an effective immune response to infection. Lagevrio will initially be given to the people who need it the most, including those that fall into one of the following categories:
Old age
Obesity
Diabetes
Heart disease
Cancer
The UK has ordered 480,000 doses of Lagevrio to be received during November. Working alongside the NHS, the government plans to administer the treatment through a national study that examines the long-term safety and effectiveness of the medicine. Both vaccinated and unvaccinated patients who fall into one of the above categories will be given the pill. Further details confirming the study particulars are to be confirmed.
Benefits
Lagevrio is the first treatment offered at home. It works best when used in mild to moderate COVID-19 cases, so its clear benefit is its ability to target infections early. Intervening in the early stages of the disease could prevent patients from requiring additional treatment and hospitals from becoming overwhelmed.
Other COVID-19 treatments currently in use include remdesivir and dexamethasone. Both have to be given intravenously or by injection, typically in a hospital setting. Lagevrio, in contrast, is a simple oral pill that can be taken at home.
https://sirelark.com/risk-insights-what-to-know-about-mercks-new-covid-19-pill/
made in the US still not approved here (wasn't even on Operation Warp Speed)
but saving lives in the UK !!!
thanks Joe
* and thanks Fauci
Post a Comment